Clinical Research in Cardiology

, Volume 100, Issue 7, pp 587–594 | Cite as

Serum soluble E-selectin and NT-proBNP levels additively predict mortality in diabetic patients with chronic heart failure

  • Judit Czúcz
  • László Cervenak
  • Zsolt Förhécz
  • Tímea Gombos
  • Zoltán Pozsonyi
  • Jan Kunde
  • István Karádi
  • Lívia Jánoskuti
  • Zoltán Prohászka
Original Paper



Neuroendocrine activation with endothelial dysfunction is a key pathophysiological process in chronic heart failure (CHF). Although increased soluble E-selectin (sE-selectin) levels predict adverse events in several forms of cardiovascular disease, there are only scarce data on its predictive value in CHF. The aim of our study was to investigate whether sE-selectin is a useful predictor of mortality in CHF patients and whether its predictive power is additive to that of NT-proBNP.


Plasma levels of sE-selectin were measured by ELISA in 192 CHF patients with clinical systolic heart failure. The study population was followed up for 14.9 months on average; 46 patients died during this period.


Levels of sE-selectin were significantly higher in non-surviving patients than in survivors (p = 0.005) and significantly correlated with the following inflammatory markers: CRP (r = 0.242, p = 0.001), TNF-α (r = 0.201, p = 0.005), TNF-RII (r = 0.207, p = 0.004), and IL-6 (r = 0.339, p < 0.0001). According to Cox regression analysis of the prediction power of sE-selectin for all-cause mortality, high sE-selectin levels independently and significantly predicted short-term mortality in CHF (HR 1.47, 95% CI 1.103–1.956). Furthermore, sE-selectin predicted mortality in CHF patients with concomitant diabetes mellitus, as well as simultaneously elevated sE-selectin and NT-proBNP levels additively predicted mortality.


This study demonstrated a weak correlation of sE-selectin level with inflammatory markers and prediction of short-term mortality in diabetic CHF patients. Elevated serum sE-selectin levels and concomitantly increased NT-proBNP concentrations have additive predictive power in CHF. This suggests that parallel activation of various pathophysiological pathways confers increased risk of adverse outcome in CHF.


Heart failure sE-selectin NT-proBNP Inflammation 



We are grateful to our patients who consented to participate in this study. The authors appreciate the skillful technical assistance of Holeczky Rudolfné, Szigeti Antalné, Korponai Gézáné, Sturmann Piroska and Kókai Márta. This study was supported by the following grants: Hungarian Scientific Research Fund (OTKA T046837, NF72689, ZP), and National Development Agency TÁMOP 4.2.2-08/01/KMR-2008-0004 (Semmelweis Bridge Project).

Conflict of interest

No financial conflicts of interest are present with regard to this manuscript by the authors.


  1. 1.
    Anker SD, von Haehling S (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90:464–470PubMedCrossRefGoogle Scholar
  2. 2.
    Devaux B, Scholz D, Hirche A, Klövekorn WP, Schaper J (1997) Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 18:470–479PubMedGoogle Scholar
  3. 3.
    Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GYH (2004) Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110:1794–1798PubMedCrossRefGoogle Scholar
  4. 4.
    Gombos T, Makó V, Cervenak L, Papassotiriou J, Kunde J, Hársfalvi J, Förhécz Z, Pozsonyi Z, Borgulya G et al (2009) Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 102:573–580PubMedGoogle Scholar
  5. 5.
    Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL (2007) C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 154:736–742PubMedCrossRefGoogle Scholar
  6. 6.
    Chong A-Y, Blann AD, Lip GYH (2003) Assessment of endothelial damage and dysfunction: observations in relation to heart failure. QJM 96:253–267PubMedCrossRefGoogle Scholar
  7. 7.
    Chong AY, Lip GYH, Freestone B, Blann AD (2006) Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand factor and soluble E-selectin. Eur J Heart Fail 8:167–172PubMedCrossRefGoogle Scholar
  8. 8.
    Roldán V, Marín F, Lip GYH, Blann AD (2003) Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 90:1007–1020PubMedGoogle Scholar
  9. 9.
    Pigott R, Dillon LP, Hemingway IH, Gearing AJ (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584–589PubMedCrossRefGoogle Scholar
  10. 10.
    Andreassen AK, Nordøy I, Simonsen S, Ueland T, Müller F, Frøland SS, Gullestad L, Aukrust P (1998) Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 81:604–608PubMedCrossRefGoogle Scholar
  11. 11.
    Potapov EV, Hennig F, Wagner FD, Volk H-D, Sodian R, Hausmann H, Lehmkuhl HB, Hetzer R (2005) Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure. Eur J Cardiothorac Surg 27:899–905PubMedCrossRefGoogle Scholar
  12. 12.
    Chong AY, Freestone B, Lim HS, Kistorp C, Gustafsson F, Hildebrandt P, Lip GYH (2007) Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study. Int J Cardiol 119:80–82PubMedCrossRefGoogle Scholar
  13. 13.
    White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin M-C, Racine N, He Y, Yao G et al (2006) Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci 110:483–489PubMedCrossRefGoogle Scholar
  14. 14.
    Kistorp C, Chong AY, Gustafsson F, Galatius S, Raymond I, Faber J, Lip GYH, Hildebrandt P (2008) Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes. Eur J Heart Fail 10:380–387PubMedCrossRefGoogle Scholar
  15. 15.
    Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GYH (2006) Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97:671–675PubMedCrossRefGoogle Scholar
  16. 16.
    Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L (2009) Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J 158:659–666PubMedCrossRefGoogle Scholar
  17. 17.
    Gombos T, Förhécz Z, Pozsonyi Z, Wallentin S, Papassotiriou J, Kunde J, Morgenthaler NG, Jánoskuti L, Prohászka Z (2009) Adrenomedullin and endothelin-1 are related to inflammation in chronic heart failure. Inflamm Res 58:298–305PubMedCrossRefGoogle Scholar
  18. 18.
    Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TM, Ahern TJ, Buurman WA (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543–549PubMedGoogle Scholar
  19. 19.
    Blann AD (2000) Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 11:623–630PubMedCrossRefGoogle Scholar
  20. 20.
    Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323:236–241PubMedCrossRefGoogle Scholar
  21. 21.
    Sharma R, Coats AJ, Anker SD (2000) The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol 72:175–186PubMedCrossRefGoogle Scholar
  22. 22.
    Suzuki T, Katz R, Jenny NS, Zakai NA, LeWinter MM, Barzilay JI, Cushman M (2008) Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 1:242–248PubMedCrossRefGoogle Scholar
  23. 23.
    Kaplanski G, Farnarier C, Benoliel AM, Foa C, Kaplanski S, Bongrand P (1994) A novel role for E- and P-selectins: shape control of endothelial cell monolayers. J Cell Sci 107:2449–2457PubMedGoogle Scholar
  24. 24.
    Emdin M, Vittorini S, Passino C, Clerico A (2009) Old and new biomarkers of heart failure. Eur J Heart Fail 11:331–335PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Judit Czúcz
    • 1
  • László Cervenak
    • 2
  • Zsolt Förhécz
    • 1
  • Tímea Gombos
    • 1
  • Zoltán Pozsonyi
    • 1
  • Jan Kunde
    • 3
  • István Karádi
    • 1
  • Lívia Jánoskuti
    • 1
  • Zoltán Prohászka
    • 1
    • 2
  1. 1.Research Laboratory, 3rd Department of Internal Medicine, Szentágothai Knowledge CenterSemmelweis UniversityBudapestHungary
  2. 2.Research Group of Inflammation Biology and ImmunogenomicsHungarian Academy of SciencesBudapestHungary
  3. 3.Department of Global Medical AffairsBRAHMS GmbHHennigsdorfGermany

Personalised recommendations